rethinkTHC Search
Menu
Study breakdown

A DNA methylation biomarker detected both tobacco and cannabis smoke exposure in high school students

Longitudinal CohortModerate evidence
The takeaway

An epigenetic biomarker (cg05575921 methylation) detected tobacco and cannabis smoke exposure in high school students, with dual users showing the greatest cumulative smoke exposure.

Adolescent medicine specialists, substance use researchers, and clinical laboratory scientists developing smoke exposure tests.

Epigenetic biomarker detected smoke exposure but not e-cigarette use

What the researchers found

Increasing proportions of students tested positive for cotinine (5-16%), THC (3-10%), and the epigenetic biomarker (5-7%) from 10th to 12th grade. Self-reported combusted tobacco and cannabis use correlated strongly with all biomarkers. The epigenetic marker did not detect e-cigarette use. Dual tobacco-cannabis users had the greatest cumulative exposure. Willingness to smoke and positive perceptions of smokers predicted biomarker positivity.

Why it matters

Self-reported substance use is unreliable in adolescents. An objective epigenetic biomarker that detects both tobacco and cannabis smoke exposure could improve screening, research accuracy, and clinical care.

The numbers in context

442 (10th grade), 376 (11th), 366 (12th) participants. Cotinine positive: 5-16%. THC positive: 3-10%. cg05575921 positive: 5-7%. Epigenetic marker correlated with combusted but not e-cigarette use. Dual users had greatest methylation changes.

How the study worked

Longitudinal study of Iowa 10th graders with a friend or family member who smoked, followed through 12th grade. Blood samples at each timepoint for serum cotinine, THC, and DNA methylation at cg05575921. Self-report data on nicotine, tobacco, cannabis, and e-cigarette use.

What this study cannot tell us

High-risk sample (all had a smoking friend or family member) limits generalizability. Epigenetic marker cannot distinguish between tobacco and cannabis smoke exposure. Blood-based testing is more invasive than saliva-based alternatives. Relatively small sample for biomarker validation.

How to read the evidence

Longitudinal validation with multiple biological markers, but high-risk sample and inability to distinguish tobacco from cannabis smoke.

When this study was published

2021 longitudinal study. Demonstrates a novel approach to objective substance use detection in adolescents.

The bigger picture

As adolescent substance use patterns shift between combusted tobacco, e-cigarettes, and cannabis, biomarkers that distinguish between routes of administration become increasingly valuable for research and clinical screening.

Questions still open

  • Could this biomarker be used in clinical screening programs? Would saliva-based versions be feasible for broader screening? Can the biomarker distinguish between heavy and light cannabis use? Does the epigenetic change reverse with cessation?

Common questions

What is an epigenetic biomarker?
Epigenetic biomarkers are chemical modifications to DNA (like methylation) that change in response to environmental exposures. The cg05575921 site shows measurable methylation changes from smoke exposure, serving as an objective indicator.
Can this test tell if a teenager is smoking cannabis?
The biomarker detects combusted smoke exposure from both tobacco and cannabis but cannot distinguish between them. It does not detect e-cigarette or non-combusted cannabis use.

Read the original research

An Examination of Risk Factors for Tobacco and Cannabis Smoke Exposure in Adolescents Using an Epigenetic Biomarker.

Frontiers in psychiatry, 12, 688384

Citation

Andersen, Allan; Gerrard, Meg; Gibbons, Frederick X; Beach, Steven R H; Philibert, Robert. (2021). An Examination of Risk Factors for Tobacco and Cannabis Smoke Exposure in Adolescents Using an Epigenetic Biomarker.. Frontiers in psychiatry, 12, 688384. https://doi.org/10.3389/fpsyt.2021.688384

Explore the wider topic